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To investigate whether polyomaviruses contribute to interstitial cystitis pathogenesis.
Subjects and Methods
A prospective study was performed with 50 interstitial cystitis cases compared with 50 age-
matched, disease-free controls for the frequency of polyomaviruria. Associations between
polyomaviruria and disease characteristics were analysed in cases. Polyomavirus in urine
and bladder tissue was detected with species (JC virus vs. BK virus) specific, real-time PCR.
Results
Case patients were reflective of interstitial cystitis epidemiology with age range from 26–88
years (median 58) and female predominance (41/50 F). There was a significant increase in
the frequency of polyomavirus shedding between cases and controls (p<0.02). Polyomavi-
rus shedding, in particular BK viruria, was associated with vesical ulceration, a marker of dis-
ease severity, among interstitial cystitis cases after adjustment for age and sex (OR 6.8,
95% CI 1.89–24.4). There was a significant association among cases between the presence
of BK viruria and response to intravesical Clorpactin therapy (OR 4.50, 95% CI 1.17–17.4).
Conclusion
The presence of polyomaviruria was found to be associated with the ulcerative form of inter-
stitial cystitis. Clorpactin, which has anti-DNA virus activity, was more likely to improve
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symptoms in the presence of BK viruria. These data from this pilot study suggest associa-
tions between polyomaviruria and interstitial cystitis warranting further investigation.
Introduction
Searching for new insights into pathogenesis and potential treatments for interstitial cystitis
is important given the high prevalence and substantial morbidity of the condition. [1] While
interstitial cystitis is currently defined as occurring only in the absence of infection [2], a
search for pathogens with potential associations with painful bladder syndrome continues,
driven by a perceived need to expand potential therapeutic targets for this disabling condi-
tion. This applies to polyomaviruses that, after establishing latent infection in the urothelium
during childhood, are frequently shed in the urine. [3] The role of BK virus (BKV), one of the
five polyomaviruses, in causing urinary pathology rather than just urinary shedding is estab-
lished. Where immunosuppressive regimens are used to prevent organ transplant rejection
BKV causes renal graft nephropathy [4] and haemorrhagic cystitis [5], particularly in haema-
tological stem cell transplants. JC virus (JCV) is even more prevalent [6] and is shed asymp-
tomatically more commonly in the urine than BKV in healthy individuals. [7] To date it has
not been linked with urinary pathology but rather, causes the cerebral white matter disease,
progressive multifocal leukoencephalopathy.
A recent, small, case-control study [8], has shown a trend to increased BKV viruria in IC
patients. In the absence of definitive evidence regarding these pathogens we have taken a sys-
tematic, prospective approach to the study of a possible pathogenic role for polyomaviruses
in interstitial cystitis. We have used a case-control study to investigate patients with cysto-




The project titled ‘Investigating the role of the polyomaviruses BKV and JCV in causing Inter-
stitial Cystitis’ was approved by the Royal Melbourne Hospital Human Research Ethics Com-
mittee and the Royal Women’s Hospital Human Research Ethics Committee; project number
2009/018 and 10/55 respectively. Written consent was obtained from all Interstitial Cystitis
patients and controls prior to enrolment in this study.
Patient and control characteristics
Patients with interstitial cystitis were identified from the Royal Melbourne Hospital Private
Medical Centre, and Royal Women’s Hospital in Melbourne, Australia. In order to be eligible
for this study, patients required a previous diagnosis of interstitial cystitis (the presence of
either glomerulations or ulceration on cystoscopy and hydrodistension) and a history consis-
tent with the Interstitial Cystitis Database Study eligibility criteria. [9]
Other patients with painful bladder syndrome who responded to oral medications, physical
therapy or bladder retraining who had never progressed to cystoscopy and hydrodistension
were excluded.
Patient records were reviewed and relevant information from the cystoscopy and hydrodis-
tension that diagnosed interstitial cystitis was recorded. Assessment of the severity of current
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interstitial cystitis symptoms was performed using the validated O’Leary-Sant symptom and
problem indices and cystoscopic findings. [10]
An age-matched cohort of controls who were selected for the absence of cystitis due to any
cause was recruited to compare the frequency of polyomaviruria with interstitial cystitis
patients. Selection of controls was consistent with the epidemiological study investigating the
prevalence of polyomaviruria performed by Zhong et al., [7] in which participants were
grouped by age into decades and not separated by gender.
Polyomavirus detection
Upon recruitment into the study, patients with interstitial cystitis and controls were screened
for the presence of urinary polyomavirus by PCR. Polyomavirus PCR testing was performed
with BKV and JCV DNA being quantified using a real-time 5’ nuclease PCR assay which
employed a probe and primers that anneal specifically to the coding region of the respective
large T antigen.
The presence of polyomavirus in bladder biopsy specimens was sought by immunohis-
tochemistry in archived biopsy material from patients with interstitial cystitis. These tissue
samples were stained with immunoperoxidase to detect the presence of polyomavirus replica-
tion, using a monoclonal antibody against the simian virus 40 (SV40) T antigen and a poly-
clonal antibody against capsid proteins SV40, which both bind human BKV and JCV. Bound
test antibodies were detected via the streptavidin-biotin method and were revealed using dia-
minobenzidine as a chromogen.
Sample size calculation and statistical method
BKV is present in the urine in up to 30% of 50–59 year old individuals and JCV in 60% of the
same population. [7] A, priori, we based sample size calculations on the assumption that BKV
would be present in 30% more interstitial cystitis patients than the general population (i.e.
BKV in 60% of interstitial cystitis patients and, using the same odds ratio, JCV in 84% of inter-
stitial cystitis patients). Under this assumption, a sample of 50 pairs of interstitial cystitis
patients and non-cystitis controls would be sufficient to detect a difference of this magnitude in
the frequency of both viruses.
The case control study used χ2 testing for comparison of the BKV and JCV prevalence
binary variable in age-matched case—control pairs. Two-sample T-testing was used to com-
pare the levels of BKV and JCV between interstitial cystitis patients and controls. Binary logis-
tic regression was used to compare the clinical characteristics of interstitial cystitis patients
with and without polyomaviruria. The characteristics analysed were ulceration as seen on cys-
toscopy, and a response to intravesical Clorpactin defined as reduction in pain, urinary fre-
quency and nocturia as determined during outpatient follow-up. Intravesical treatment with
Clorpactin is not offered at Royal Women’s Hospital, therefore these patients were not
included in the analysis of a response to Clorpactin.
Cystoscopic treatment
Prior to treatment with cystoscopy, hydrodistension and intravesical Clorpactin, all patients
were refractory to alternative therapy including amitriptyline, bladder retraining and pelvic
muscle therapy, non-steroidal anti-inflammatory agent, pentosan polysulphate and DMSO
intravesical instillations. Cystoscopy and hydrodistension was performed in a standardized
fashion. [11]
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Results
A total of 107 patients with previously diagnosed interstitial cystitis were invited to participate
in the study. Forty-four of these either declined to participate in the study, or were unable to be
contacted. Eight patients who returned the consent form were subsequently deemed ineligible
as they no longer satisfied the ICDB criteria, either due to a change in diagnosis, bladder
removal or resolution of urinary symptoms. Five patients were lost to follow-up and therefore
unable to provide a urine specimen for testing.
Fifty patients with interstitial cystitis and fifty age-matched controls without cystitis were
investigated for polyomaviruria. Case control demographics are demonstrated in Table 1, with
no significant difference in age-matching of cases and controls (p = 0.82).
Polyomavirus urinary shedding was more prevalent in patients with interstitial cystitis com-
pared to age-matched controls. (p<0.02). Table 1. Urinary viral loads were log10-transformed
for statistical analysis. There was a significant difference in the mean levels of JC virus urinary
shedding in patients with interstitial cystitis compared to controls. (p<0.02). A trend to higher
levels of BKV was also present.
Cystoscopic and hydrodistension data were available for 49/50 patients with interstitial cys-
titis, 27 of whom had ulceration. Significant associations were present between urinary shed-
ding of both polyomaviruses and ulceration; (BKV: OR 6.80, 95% CI 1.89–24.2 and JCV: 4.29,
1.29–14.26). Polyomavirus urinary shedding was also positively associated with ulceration at
cystoscopy. Twenty of the 23 patients treated with Clorpactin demonstrated symptomatic
improvement during outpatient review post cystoscopy. A beneficial response to intravesical
Clorpactin was correlated specifically with BKV urinary shedding (OR = 4.50, 95% CI 1.17–
17.4). A non-significant trend to Clorpactin response and JCV polyomaviruria was also present
(2.79, 0.77–10). Of the 20 patients reporting benefit following Clorpactin, 14 of these had the
ulcerative form of interstitial cystitis. The three patients who did not respond to Clorpactin all
had the non-ulcerative form of interstitial cystitis. O’Leary-Sant questionnaires were available
for 43/50 patients, with a mean score of 17.6 and range 3–34. No association existed between
O’Leary-Sant symptom severity and polyomavirus urinary shedding (p = 0.78).
Thirteen interstitial cystitis patients with polyomaviruria had archived bladder tissue biopsy
examined for evidence of polyomaviruses. Six interstitial cystitis patients without polyomavir-
uria also had their bladder tissue biopsy examined. Bladder biopsy samples analysed were
taken up to ten years ago. PCR testing of bladder tissue biopsies of these 19 patients yielded
one positive result for polyomavirus DNA. A weakly positive level of JCV was detected in an
interstitial cystitis patient with polyomavirus viruria. This 81-year-old female had BKV and
JCV present in her urine, both at a viral load of 107 copies per mL. This female had the
Table 1. Case control analysis.
IC cases Controls
Age range 26–88 20–87
Mean age 57.44 56.66
Median age 58.5 58.5
Sex—female n (%) 41 (82) 27 (54) 0.69
Polyomaviruria n (%) 28 (56) 16 (32) 0.02
Mean BKV urinary load log10 2.92 1.84 0.09
Mean JCV urinary load log10 3.29 1.74 0.02
Interstitial cystitis cases and disease free control demographics and associations with polyomaviruria.
doi:10.1371/journal.pone.0137310.t001
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presence of ulceration and glomerulations on cystoscopy, a response to treatment with Clor-
pactin and a severity score of 10; all factors that indicate that her IC was severe. The biopsy was
taken in August 2001. Polyomavirus immunohistochemistry tests performed on the 19 bladder
tissue biopsy samples were all negative.
Discussion
Possible links between interstitial cystitis causation and infection have been sought repeatedly
to date. Bacterial pathogens that frequently cause urinary tract infection like Escherichia coli
and cell-wall deficient organisms such asMycoplasma hominis were studied, among others,
showing no associations. [12] Similarly, viruses that establish latent or persistent infection like
herpes simplex, adenovirus, cytomegalovirus, and human papillomavirus were absent from the
bladder biopsies of interstitial cystitis patients. [13] Polyomavirus detection was not included
in the study methodology.
Our study builds on previous attempts to that have shown a possible contribution of poly-
omavirus infection to the pathogenesis of IC. [14] The recent study of patients with IC com-
pared with controls with non-cystitis associated urological conditions showed a non-
significant trend to higher incidence of BKV shedding in IC patients with ulceration. [8]
We have previously reported a single case of interstitial cystitis occurring in a diabetic man
who was successfully treated with intravesical cidofovir. A substantial, 5-log10, reduction in
the urinary PCR levels of polyomaviruses was seen with intravesical cidofovir, which coincided
with a sustained reduction in symptoms of painful bladder syndrome. [15] This individual had
been refractory to a full spectrum of therapeutic approaches and symptoms of his IC were
extremely severe.
In this pilot study we have demonstrated a number of significant associations between inter-
stitial cystitis and polyomaviruses warranting further investigation of the relationship. There
was a significant increase in polyomaviral shedding when interstitial cystitis cases were com-
pared with age matched disease free controls. The ulcerative form of the disease, typically
occurring in patients with lower volume under anaesthetic was significantly associated with the
presence of polyomavirus. Whether this finding represents cause or effect is uncertain as vesi-
cal ulceration may predispose to greater shedding of latent virus from the denuded urothelium.
Despite no infection being found as a cause of interstitial cystitis to date, the search for
infective precipitants for some patients with interstitial cystitis is still important as new treat-
ments may then be considered for this disabling condition. We believe that polyomaviruses are
possible contributors to the pathogenesis of interstitial cystitis. These viruses occur commonly
in the population with seroprevalence of approximately 80% and 40–60% for BKV and JCV
respectively. [6] The fact that polyomaviruses establish latency in the urothelium with frequent,
asymptomatic shedding [7], distinguishes them from other viruses examined previously in
interstitial cystitis patients. The pathogenicity of BKV in the urogenital tract is established. In
the setting of haematopoietic stem cell transplantation, severe BKV haemorrhagic cystitis may
be lethal. [16]
Our study provides us with evidence of polyomaviruses’ association with IC compared with
a cohort of unselected controls with no symptoms of cystitis. It may possibly be instructive to
perform a validation study with a control group consisting of patients with other forms of cysti-
tis such as recurrent bacterial infection. As we have suggested above, it may be that where the
bladder is inflamed, polyomavirus shedding may be more prevalent therefore reducing or
negating the effect size we have seen in this study.
Polyomaviruses were only detected in one of the interstitial cystitis patients’ bladder biopsy
specimens. The biopsies were typically obtained from the posterior wall of the bladder
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consistent with common Urological practice. Cystoscopic biopsies are not taken from ulcera-
tive areas because of the risk of bladder perforation. This low yield for polyomavirus detection
in the bladder tissue may be due to sampling error, the archival nature of the specimens, shed-
ding from the upper urinary tract or it may be negative evidence for a causative association
between interstitial cystitis and polyoma virus. Future studies could include biopsies in the
vicinity of the ulcerative area with small cold cup biopsies.
Therapeutic options for interstitial cystitis related to polyomaviruria may be opened up if
this association is borne out by further studies. Fluoroquinolones like ciprofloxacin [17], and
other agents, both antiviral (cidofovir) [18] and immunomodulatory (leflunamide) [19] have
all been shown to have anti-polyomavirus activity in vitro. Of particular relevance to existing
treatments used in interstitial cystitis, Clorpactin has been shown to have in vitro antiviral
activity against DNA viruses including vaccinia and herpes simplex along with the RNA virus
HIV. [20] Clorpactin has not been tested yet for polyomavirus activity and this along with Pen-
tosan polysulfate sodium (Elimiron), and iAluril, should be investigated for anti-polyomavirus
activity. In patients with low capacity (typically ulcerative) interstitial cystitis, many of whom
are considered for radical therapy such as urinary diversion, we would recommend studies to
determine if polyomaviruria is present before such radical measures and consideration of fur-
ther therapy with Clorpactin.
Reports of therapeutic use of lower concentrations of Clorpactin suggest that there may be
opportunities to systematically compare this with other agents possessing anti-viral or other
therapeutic effect. Compelling patient testimonials who had only cystectomy and diversion
as an option when they used Clorpactin led to its more widespread use when other treatments
had failed. We are aware that there has been a medical trend against this agent though it is
possible it may have been an innocent bystander in the reported cases. [21] The small risk of
ureteral fibrosis should be mitigated against by prospective detection of vesico-ureteral reflux
cystogram prior to its use. In cases where reflux was present, ureteral occlusion balloons were
used. In future our use of Clorpactin is likely to be in the context of clinical research. We
have had no complications with its use and repeated use has been associated with bladder
preservation rather than progressive loss of bladder volume associated with repeated bladder
cautery.
Potentially higher levels of endogenous steroids due to chronic pain could influence the fre-
quency of polyomaviruria in cases with interstitial cystitis. None of the fifty cases with intersti-
tial cystitis were taking exogenous steroids, however the effect of chronic pain on endogenous
steroid levels was not studied. This weakness could be addressed by including a control group
of patients with chronic pain syndromes to test for polyomavirus frequency. Furthermore,
ACTH, CRF, sympathetic nervous system responses and diurnal salivary cortisol levels could
be studied.
A weakness of this study is that the data used for assessing a response to Clorpactin was ret-
rospective. Patient records were reviewed, and information was obtained from the follow-up
appointment three months post treatment. The treating clinician determined a response to
Clorpactin as symptom reduction, improvement in voided volumes and reduced nocturia for
longer than 3 months. Hydrodistension alone has been demonstrated to have symptomatic
benefit for a few weeks [22], therefore symptomatic reduction in the manner of 2–4 weeks was
not considered significant, and these patients were classified as non-responders for the purpose
of the study. There were twenty responders and 3 non-responders to Clorpactin, all of which
returned the questionnaire. O’Leary-Sant questionnaires were conducted post-treatment to
investigate a relationship between polyomavirus shedding and symptom severity. Prospective
analysis of a response to Clorpactin and novel agents such as iAluRil would allow the use of pre
and post-treatment urinary testing and O’Leary-Sant questionnaires. Another weakness was
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that recent treatment for interstitial cystitis was not analysed prior to the collection of the ques-
tionnaires, which could potentially bias symptom severity and urinary polyomavirus shedding.
Interstitial cystitis is a common and disabling condition. The antecedent injuries and abnor-
malities that lead to the endpoint of a denuded urothelial glyclosaminoglycan layer may be
contributed to either primarily by polyomavirus shedding. Alternately, patients with interstitial
cystitis may develop ulceration due to polyomavirus shedding. In either scenario, polyomavir-
uria in interstitial cystitis may identify a group of these patients who could benefit from tar-
geted anti-infective therapy, particularly with Clorpactin.
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